Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients

NCT02024477 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Saxagliptin
DRUG: Placebo

Sponsor

George Washington University

Collaborators

[object Object]